Indication
HER2-expressing Gastrointestinal Cancers
1 clinical trial
8 products
Product
ZW25Product
LeucovorinClinical trial
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)Status: Active (not recruiting), Estimated PCD: 2025-11-28
Product
CisplatinProduct
CapecitabineProduct
FluorouracilProduct
BevacizumabProduct
OxaliplatinProduct
Gemcitabine